Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $28.4500 (-0.66%) ($27.4500 - $28.6800) on Sat. Jun. 2, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.14% (three month average) | RSI | 31 | Latest Price | $28.4500(-0.66%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.5% a day on average for past five trading days. | Weekly Trend | ADMS declines -5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting ADMS price | ADMS will decline at least -1.57% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.57% (StdDev 3.14%) | Hourly BBV | 0 () | Intraday Trend | -0.8% | | | |
|
1 - 5 Day Possible Target | $20.57(-27.7%) | Resistance Level | $30.32 | 5 Day Moving Average | $28.71(-0.91%) | 10 Day Moving Average | $29.4(-3.23%) | 20 Day Moving Average | $30.32(-6.17%) | To recent high | -12.9% | To recent low | 25.8% | Market Cap | $N/A | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |